John Volpone
CIK: 0002081729
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
X4 Pharmaceuticals, Inc
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 12, 2026XFOR
X4 Pharmaceuticals, Inc
Sale(S)Direct24.6K shares at avg. $4.44$109K - Oct 29, 2025XFOR
X4 Pharmaceuticals, Inc
Award(A)DirectStock Option (right to buy)
2.3M shares- - Aug 14, 2025XFOR
X4 Pharmaceuticals, Inc
Award(A)Direct289.9K shares- - Aug 12, 2025XFOR
X4 Pharmaceuticals, Inc
Award(A)DirectStock Option (right to buy)
1.6M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 | XFOR X4 Pharmaceuticals, Inc | Sale(S) | 24,576 | $4.44 | $109,228 | Direct |
| Oct 29, 2025 | XFOR X4 Pharmaceuticals, Inc | Award(A) Stock Option (right to buy) | 2,329,154 | - | - | Direct |
| Aug 14, 2025 | XFOR X4 Pharmaceuticals, Inc | Award(A) | 289,881 | - | - | Direct |
| Aug 12, 2025 | XFOR X4 Pharmaceuticals, Inc | Award(A) Stock Option (right to buy) | 1,609,873 | - | - | Direct |
1-4 of 4 transactions
About Volpone John
Volpone John (SEC CIK 0002081729) files insider reports with the SEC as President of X4 Pharmaceuticals, Inc (XFOR).
Signal8 holds 4 ownership filings by Volpone John (1 Form 3, 3 Form 4), filed between Aug 14, 2025 and Aug 13, 2026. Those filings report 4 transactions, from Aug 12, 2025 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Volpone John's filings is in BOSTON, MA.
Recent filings by Volpone John
Other insiders filing for X4 Pharmaceuticals, Inc (XFOR)
- Craig Adam R, Executive Chairman
- KIRSKE DAVID, Chief Financial Officer
- Gold Kelly, Director
- Bridger Gary, Director
- de Craecker Francoise, Director
- WYZGA MICHAEL S, Director